TCL Archive Comprehensive Centers Balk At “Requiring” All Control Programs To Be Funneled Through Them December 5, 1975
TCL Archive How Low Can You Go? ODAC Accepts Retrospective Study for Accelerated Approval September 30, 2011
TCL Archive Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa. January 7, 2005
TCL Archive FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly. May 6, 2005